Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent Deferred RevenueGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Metlife (MET) Cash & Equivalents (2016 - 2026)

Metlife's Cash & Equivalents history spans 18 years, with the latest figure at $11.2 billion for Q1 2026.

  • Quarterly Cash & Equivalents fell 47.48% to $11.2 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $11.2 billion through Mar 2026, down 47.48% year-over-year, with the annual reading at $22.0 billion for FY2025, 85.14% up from the prior year.
  • Cash & Equivalents came in at $11.2 billion for Q1 2026, down from $22.0 billion in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $23.5 billion in Q1 2022 to a low of $1.3 billion in Q4 2022.
  • The 5-year median for Cash & Equivalents is $12.0 billion (2024), against an average of $14.4 billion.
  • Year-over-year, Cash & Equivalents crashed 70.8% in 2023 and then surged 293.91% in 2024.
  • Metlife's Cash & Equivalents stood at $1.3 billion in 2022, then surged by 134.19% to $3.0 billion in 2023, then soared by 293.91% to $11.9 billion in 2024, then surged by 85.14% to $22.0 billion in 2025, then crashed by 49.16% to $11.2 billion in 2026.
  • Per Business Quant, the three most recent readings for MET's Cash & Equivalents are $11.2 billion (Q1 2026), $22.0 billion (Q4 2025), and $20.2 billion (Q3 2025).